Clinical trials: Unfractionated Heparin
Extracorporeal Membrane Oxygenation Complication, Pediatric ALL
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
The investigators will prospectively enroll 30 neonatal and pediatric ECMO patients at a single pediatric Level 1 trauma center.
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants
- Trial name
- NCT03318393
- Testing
- Bivalirudin, Unfractionated heparin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Cardiogenic Shock
HEROIC (Heparin Requirement in Counterpulsation)
Patients with intra-aortic balloon pumps (catheters placed in the groin connected to a pump which assists the heart by opening and closing a balloon in the aorta, thereby decreasing the work of the heart and improving blood flow…
- Trial name
- HEROIC (NCT00445211)
- Testing
- Heparin, Without Heparin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Corewell Health East
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Deep Vein Thrombosis, Venous Thrombosis
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Assess the relative change in thrombus volume as determined by two assessments (Baseline and Day 14-21) with magnetic resonance venography (MRV) in subjects with deep-vein thrombosis (DVT) treated with either an edoxaban…
- Trial name
- eTRIS (NCT01662908)
- Testing
- edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin
- Where
- 34 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- Daiichi Sankyo
Peripheral Vascular Diseases
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.
- Trial name
- VIPER (NCT00541307)
- Testing
- Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- W.L.Gore & Associates
End-stage Renal Disease
Propaten Randomized Investigation on Cost-benefit and Efficacy
The purpose for this study is to evaluate the patency and outcomes of conventional and heparin anticoagulant bonded arteriovenous grafts in patients with end stage renal disease.
- Trial name
- PRICE (NCT01601873)
- Testing
- PROPATEN, Standard Graft
- Where
- 5 sites in United States
- Volunteers
- 103 people
- Sponsor
- The University of Texas Health Science Center, Houston
Thrombocytopenia
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
Heparin-induced thrombocytopenia (HIT), a condition characterized by low platelet levels and possible blood clots, occurs in a small number of people after treatment with the drug heparin.
- Trial name
- HOT (NCT00594685)
- Where
- 21 sites in United States
- Volunteers
- 10 people
- Sponsor
- Carelon Research
End Stage Renal Disease
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
This study will investigate the effect of co-administration of Triferic and heparin on the ability to maintain circuit anti-coagulation and iron delivery when compared to control conditions when each treatment is administered via…
- Trial name
- NCT04042324
- Testing
- Triferic, Heparin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Venous Thromboembolism
Once Weekly Subcutaneous Ports for the Administration of Anticoagulants
The purpose of this study is to ascertain whether subcutaneous ports are an effective and reliable way to administer the low molecular weight heparin (LMWH) enoxaparin to patients for the prevention or treatment of venous…
- Trial name
- NCT00774748
- Testing
- Insuflon
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of North Carolina, Chapel Hill
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
This study will assess the safety and efficacy of heparin free hemodialysis (HD) performed with dialyzers with Endexo in adult end-stage renal disease (ESRD) subjects on thrice-weekly in-center HD.
- Trial name
- NCT04511338
- Testing
- Dialyzer with Endexo
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fresenius Medical Care North America
Catheter-Associated Infections, Catheter-Related Infections
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
The objective of this Phase I/II pilot study is to evaluate the safety and effectiveness of a non- antibiotic chelator based lock solution that contains nitroglycerin in combination with sodium citrate and ethanol (NiCE lock…
- Trial name
- NCT02577718
- Testing
- Nitroglycerin-citrate-ethanol (NiCE)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novel Anti-Infective Technologies, LLC
Thrombosis
Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.
- Trial name
- DESIR-ABLE (NCT00913133)
- Testing
- Desirudin
- Where
- 16 sites in United States
- Volunteers
- 516 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Coronary Artery Disease (CAD)
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).
- Trial name
- EMINENCE (NCT00543400)
- Testing
- M118, Unfractionated Heparin
- Where
- 44 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Venous Thromboembolic Disease, Deep Vein Thrombosis
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of…
- Conditions
- Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT01729559
- Testing
- 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Scripps Health
Thromboembolism
Self-management of Low Molecular Weight Heparin Therapy
There is very little data available on compliance with self-injected low molecular weight heparins (LMWH), but what there is, definitely shows that compliance represents a significant problem.
- Trial name
- NCT00794560
- Testing
- patient education
- Where
- 2 sites in Switzerland
- Volunteers
- 154 people
- Sponsor
- University Hospital, Basel, Switzerland